Sofinnova Partners raises $370.3 million for its early-stage healthcare fund to invest in healthtech and life sciences startups

Investments in healthcare and Life Sciences startups continue to soar. Now, the sector is boosted by today’s announcement from Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences.

Today, Sofinnova announced it has closed $370.3 million ( €333 million) for its latest early-stage healthcare venture capital fund Sofinnova Capital IX. The firm now has more than €2B under management with more than €1B raised in the last four years across its platform of life sciences funds.

Founded about half of a decade ago, Sofinnova Partners  is a leading European venture capital firm specialized in Life Sciences. They invest in start-ups, early-stage companies, corporate spin-offs and occasionally turnaround situations. They invest in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). To date, Sofinnovahas backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

The new fund has commitments from leading institutional investors, predominantly endowment funds, insurance companies, pension funds, sovereign funds, corporates and family offices, many of whom are continuing a long and successful relationship with the Sofinnova family of Funds. The majority of commitments came in from Europe, including France, Italy, Ireland, Denmark, Germany, Switzerland, the United Kingdom and Luxembourg, but also from leading North American investors in the U.S. and Canada, as well as major investors from Asia.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said, “Our experienced team, stable strategy and exit track record resonated well with investors, hence the success of our fundraising for this latest Capital fund. Over the last three years, we have completed nine remarkable exits in the portfolio for a total enterprise value of almost 4 billion euros.”

The launch of Sofinnova Capital IX follows the formation, in just the last three years, of Sofinnova Crossover I, a fund investing in pre- and post-IPO companies; Sofinnova MD Start III, a medical device acceleration fund; Sofinnova Industrial Biotech I, a fund dedicated to industrial biotech; and Sofinnova Telethon Fund I, a fund dedicated to seed investments in gene and cell therapies based out of Milan, Italy. With these focused franchises managed by dedicated specialist teams, Sofinnova Partners has established a unique and comprehensive platform of investment vehicles across the life sciences investment value chain.